References
- 1. McMahan ZH, Hummers LK. Gastrointestinal involvement in systemic sclerosis: diagnosis and management. Curr Opin Rheumatol. 2018;30:533-540.10.1097/BOR.000000000000054530234725
- 2. Denaxas K, Ladas SD, Karamanolis GP. Evaluation and management of esophageal manifestations in systemic sclerosis. Ann Gastroenterol. 2018;31:1-6.10.20524/aog.2018.0228582594629507463
- 3. Tétreault MP, Kahrilas P. GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis. Curr Rheumatol Rep. 2019;21;42.10.1007/s11926-019-0841-x885283831270707
- 4. Miller JB, Gandhi N, Clarke J, McMahan Z. Gastrointestinal Involvement in Systemic Sclerosis: An Update. J Clin Rheumatol. 2018;24:328-337.10.1097/RHU.0000000000000626611037729095721
- 5. Schmeiser T, Saar P, Jin D, et al. Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatol Int. 2012;32:2471-2478.10.1007/s00296-011-1988-621769490
- 6. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clinic Rev Allerg Immunol. 2017;53:306-336.10.1007/s12016-017-8625-428712039
- 7. Anton E. Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol. 2016;13:461-472.10.1038/nrgastro.2016.9927381075
- 8. Lynch S, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016;375:2369-2379.10.1056/NEJMra160026627974040
- 9. Vogelzang A, Guerrini MM, Minato N, Fagarasan S. Microbiota – an amplifier of autoimmunity. Curr Opin Immunol. 2018;55:15-21.10.1016/j.coi.2018.09.00330248521
- 10. Tallota R, Atzeni F, Ditto MC, Gerardi MC, Sarzi-Puttini P. The Microbiome in Connective Tissue Diseases and Vasculitides: An Update Narrative Review. J Immunol Res. 2017; 2017:6836498.10.1155/2017/6836498555660928835902
- 11. Tong Y, Marion T, Schett G, Luo Y, Liu Y. Microbiota and metabolites in rheumatic diseases. Autoimmun Rev. 2020;19:102530.10.1016/j.autrev.2020.102530
- 12. Konig MF. The microbiome in autoimmune rheumatic disease. Best Pract Res Clin Rheumatol. 2020;34:101473.10.1016/j.berh.2019.101473
- 13. Asano Y. The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies. J Clin Med. 2020;9:2687.10.3390/jcm9092687
- 14. Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. Semin Arthritis Rheum. 2016;46:115-123.10.1016/j.semarthrit.2016.02.005
- 15. Smirani R, Poursac N, Naveau A, Schaeverbeke T, Devillard R, Truchetet ME. Orofacial consequences of systemic sclerosis: A systematic review. J Scleroderma Relat Disord. 2018;3:88-90.10.1177/2397198317746966
- 16. Hadj Said M, Foletti J, Graillon N, Guyot L, Chossegros C. Orofacial manifestations of scleroderma. A literature review. Rev Stomatol Chir Maxillofac Chir Orale. 2016;117:322-326.
- 17. Jung S, Martin T, Schmittbuhl M, Huck O. The spectrum of orofacial manifestations in systemic sclerosis: a challenging management. Oral Dis. 2017;23:424-439.10.1111/odi.12507
- 18. Gomes da Silva G, Maymone de Melo M, Leão J, et al. Oral features of systemic sclerosis: A case control study. Oral Dis. 2019;25:1995-2002.10.1111/odi.13174
- 19. Baron M, Hudson M, Tatibouet S, et al. The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. Rheumatology (Oxford). 2014;53:1386-1394.10.1093/rheumatology/ket441
- 20. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005;366:1809-1820.10.1016/S0140-6736(05)67728-8
- 21. Isola G, Williams RC, Lo Gullo A, et al. Risk association between scleroderma disease characteristics, periodontitis, and tooth loss. Clin Rheumatol. 2017;36:2733-2741.10.1007/s10067-017-3861-928988297
- 22. Cheng Z, Meade J, Mankia K, Emery P, Devine DA. Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017;31:1-12.10.1016/j.berh.2017.08.00129221594
- 23. Kobak S, Oskel F, Aksu K, Kabasakal Y. The frequency of sicca symptoms and Sjogren’s syndrome in patients with systemic sclerosis. Int J Rheum Dis. 2013;16:88-92.10.1111/j.1756-185X.2012.01810.x23441777
- 24. Denaxas K, Ladas SD, Karamanolis GP. Evaluation and management of esophageal manifestations in systemic sclerosis. Ann Gastroenterol. 2018;31:165-170.10.20524/aog.2018.0228582594629507463
- 25. Roberts CGP, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55:1697-1703.10.1136/gut.2005.086074185646216527835
- 26. Kumar S, Singh J, Rattan S, DiMarino A, Cohen S, Jimenez S. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. Aliment Pharmacol Ther. 2017;45:883-898.10.1111/apt.13963557644828185291
- 27. Lee JS, Kim HS, Moon JR, et al. Esophageal involvement and Determinants of Perception of Esophageal Symptoms Among South Koreans With Systemic Sclerosis. J Neurogastroenterol Motil. 2020;26:477-485.10.5056/jnm19148754719632989185
- 28. Arana-Guajardo AC, Barrera-Torres G, Villarreal-Alarcón MÁ, Vega-Morales D, Esquivel-Valerio JA. Esophageal symptoms and their lack of association with high-resolution manometry in systemic sclerosis patients. Reumatol Clin. 2017;15:165-169.10.1016/j.reuma.2017.09.00529258795
- 29. Crowell MD, Umar SB, Griffing LW, DiBase JK, Lacy BE, Vela MF. Esophageal Motor Abnormalities in Patients With Scleroderma: Heterogeneity, Risk Factors, and Effects on Quality of Life. Clin Gastroenterol Hepatol. 2017;15:207-213.10.1016/j.cgh.2016.08.03427613260
- 30. De Carlan M, Lescoat A, Brochard C, et al. Association between clinical manifestations of systemic sclerosis and esophageal dysmotility assessed by high-resolution manometry. J Scleroderma Relat Disord. 2017;2:50-56.10.5301/jsrd.5000233
- 31. Nicola S, Rolla G, Bucca C, et al. Gastric Juice Expression of Th-17 and T-Reg Related Cytokines in Scleroderma Esophageal Involvement. Cells. 2020;19;2106.10.3390/cells9092106756448032947843
- 32. Snyder DL, Crowell MD, Kahn A, Griffing WL, Umar S, Ramirez FC. Prevalence of Barrett’s Esophagus in Female Patients With Scleroderma. Am J Gastroenterol. 2020;116:517-521.10.14309/ajg.000000000000110933657040
- 33. Petcu A, Ghib LJ, Grad SM, et al. Upper gastrointestinal involvement in systemic sclerosis: Findings in a real-life setting. Exp Ther Med. 2019;18:5095-5100.10.3892/etm.2019.8125688039531798729
- 34. Grusell NE, Dahlén G, Ruth M, et al. Bacterial flora of the human oral cavity, and the upper and lower esophagus. Dis Esophagus. 2012;53:650-656.
- 35. D’Souza SM, Cundra LB, Yoo BS, Parekh PJ, Johnson DA. Microbiome and Gastroesophageal Disease: Pathogenesis and Implications for Therapy. Ann Clin Gastroenterol Hepatol. 2020;4:020-033.10.29328/journal.acgh.1001018
- 36. Espinoza M, Mehta BK, Wang Y, et al. Characterization of the Esophageal Microbiome in Patients with Systemic Sclerosis (SSc). Arthritis Rheumatol. 2018;Suppl70.
- 37. Hong BY, Giang R, Mbuagbaw L, Larche M, Thabane L. Factors associated with development of gastrointestinal problems in patients with scleroderma: a systematic review. Syst Rev. 2015;4:188.10.1186/s13643-015-0176-2469731826718896
- 38. Radić M. Role of Helicobacter pylori infection in autoimmune systemic rheumatic diseases. World J Gastroenterol. 2014;20:12839-12846.10.3748/wjg.v20.i36.12839417746625278681
- 39. Yong W, Upala S, Sanguankeo A. Helicobacter pylori infection in systemic sclerosis: a systematic review and meta-analysis of observational studies. Clin Exp Rheumatol. 2018;36(Suppl.113): S168-S174.
- 40. Radić M, Kaliterna MD, Bonacin D, et al. Is Helicobacter pylori infection a risk factor for disease severity in systemic sclerosis? Rheumatol Int. 2013;33:2943-2948.
- 41. Yamaguchi K, Iwakiri R, Hara M, et al. Reflux Esophagitis and Helicobacter pylori Infection in Patients with Scleroderma. Inter Med. 2008;47:1555-1559.10.2169/internalmedicine.47.112818797112
- 42. Ram M, Barzilai O, Shapira Y, et al. Helicobacter pylori serology in autoimmune diseases: fact or fiction? Clin Chem Lab Med. 2013;51:1075-1082.
- 43. Bilgin H, Kocabaș H, Keșli R. The prevalence of infectious agents in patients with systemic sclerosis. Turk J Med Sci. 2015;45:1192-1197.10.3906/sag-1404-150
- 44. Balaji C, Bhuvanesh M, Saranya C, Ramesh R, Saravanan M, Rajeswari S. Helicobacter Pylori infection in Systemic Sclerosis and Its Association with Upper Gastrointestinal Dysfunction. Indian J Rheumatol. 2017;12:204-208.10.4103/injr.injr_62_17
- 45. Efthymiou G, Liaskos C, Siamopoulou T, et al. Antigen-specific humoral responses against Helicobacter pylori in patients with systemic sclerosis. Immunol Res. 2020;68:39-47.10.1007/s12026-020-09124-w32253703
- 46. Quigley EM. Small Intestinal Dysmotility, Its Role in Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth: Assessment and Management. Front Gastrointest Res Basel Karger. 2014;33:55-64.10.1159/000356743
- 47. Rawn S, Pitman N, Beattie K, Bazzaz A, Larche M. Small Intestinal Bacterial Overgrowth in Patients with Systemic Sclerosis. Indian J Rheumatol. 2017;12:S167-S170.10.4103/0973-3698.219077
- 48. Feng X, Li XQ, Jiang Z. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol. 2021 January. [Epub ahead of print]10.1007/s10067-020-05549-833426631
- 49. Marie I, Ducrotté P, Denis P, Menard JF, Levesque H. Small Intestinal bacterial overgrowth in systemic sclerosis. Rheumatology. 2009;48:1314-1319.10.1093/rheumatology/kep22619696066
- 50. Polkowska-Pruszyńska B, Gerkowicz A, Rawicz-Pruszyński K, Krasowska D. The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO). Diagnostics. 2020;10:587.10.3390/diagnostics10080587745988232823752
- 51. Preis E, Franz K, Siegert E, et al. The impact of malnutrition on quality of life in patients with systemic sclerosis. Eur J Clin Nutr. 2018;72:504-510.10.1038/s41430-018-0116-z29520082
- 52. Zou H, De Palma G, Bercik P, Verdu E, Beattie K, Larche M. Distinct Characteristics of the Gut Microbiome of Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth [abstract]. Arthritis Rheumatol. 2019;71(suppl10).
- 53. Parodi A, Sessarego M, Greco A, et al. Small Intestinal Bacterial Overgrowth in Patients Suffering From Scleroderma: Clinical Effectiveness of Its Eradication. Am J Gastroenetrol. 2008;103: 1257-1262.10.1111/j.1572-0241.2007.01758.x18422815
- 54. Fynne L, Worsøe J, Gregersen T, Schalageter V, Laurberg S, Krogh K. Gastrointestinal transit in patients with systemic sclerosis. Scand J Gastroenterol. 2011;46:1187-1193.10.3109/00365521.2011.60315821815862
- 55. Gemignani L, Savarino V, Ghio M, et al. Lactulose Breath Test to Assess Orocecal Transit Delay and Estimate Esophageal Dysmotility in Scleroderma Patients. Semin Arthritis Rheum. 2013;42:522-529.10.1016/j.semarthrit.2012.09.00423352249
- 56. Savarino E, Mei F, Parodi A, et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology. 2013;52:1095-1100.10.1093/rheumatology/kes42923382360
- 57. Tauber M, Avouac J, Benahmed A, et al. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol. 2014;32:S82-S87.
- 58. Soukup T, Cyrany J, Kopacova M, Tacheci I, Bures J. Small intestinal bacterial overgrowth in patients with systemic sclerosis, clinical data relevance [abstract]. Clin and Exp Rheumatol. 2014;32:S132.
- 59. Marie I, Leroi A, Menard J, Levesque H, Quillard M, Ducrotte P. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev. 2015;14:547-554.10.1016/j.autrev.2015.01.01825661980
- 60. Adarsh M, Sharma S, Sinha S, et al. Gastrointestinal Dysmotility and Infections in Systemic Sclerosis – An Indian Scenario. Curr Rheumatol Rev. 2017;13.
- 61. Cruz-Dominguez M, Garcia-Collinot G, Madrigal-Santillan E, et al. Small intestinal bacterial overgrowth in relation to gastrointestinal symptoms in systemic sclerosis [abstract]. Ann Rheum Dis. 2017;103:1282.
- 62. Sawadpanich K, Soison P, Chunlertrith K, et al. Prevalence and associated factors of small intestinal bacterial overgrowth among systemic sclerosis patients. Int J Rheum Dis. 2019;22:695-699.10.1111/1756-185X.1349530729669
- 63. García-Collinot G, Madrigal-Santillán EO, Martínez-Benzomo MA, et al. Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Dig Dis Sci. 2020;65:1134-1143.10.1007/s10620-019-05830-031549334
- 64. Zhang X, Chen Bd, Zhao Ld, Li H. The Gut Microbiota: Emerging Evidence in Autoimmune Diseases. Trends Mol Med. 2020;26:862-873.10.1016/j.molmed.2020.04.00132402849
- 65. Volkmann E, Chang Y, Barroso N, et al. Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium. Arthritis Rheumatol. 2016;68:1483-1492.10.1002/art.39572556166626749064
- 66. Andrnasson K, Alrawi Z, Persson A, Jonsson G, Marsal J. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res Ther. 2016;18:278.10.1186/s13075-016-1182-z512698627894337
- 67. Bosello S, Paroni Sterbini F, Natalello G, et al. The intestinal involvement in systemic sclerosis is characterized by a peculiar gut microbiota [abstract]. Arthritis Rheumatol. 2016;68.
- 68. Volkmann E, Hoffman-Vold A, Chang Y, et al. Systemic sclerosis is associated with alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol. 2017;4: e000134.10.1136/bmjgast-2017-000134550863628761687
- 69. Patrone V, Puglisi E, Cardinali M, et al. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. Sci Rep. 2017;7:14874.10.1038/s41598-017-14889-6566591229093509
- 70. Bellocchi C, Fernandez-Ochoa A, Montanelli G, et al. Microbial and metabolic multi-omic correlations in systemic sclerosis patients. Ann N Y Acad Sci. 2018;1421:97-109.10.1111/nyas.1373629749635
- 71. Natalello G, Bosello S, Paroni Sterbini F, et al. Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status. Clin Exp Rheumatol. 2020;38(Suppl. 125).
- 72. Bellocchi C, Volkmann ER. Update on the Gastrointestinal Microbiome in Systemic Sclerosis. Curr Rheumatol Rep. 2018;20:49.10.1007/s11926-018-0758-929943234